OS Therapies

07/31/2026

For many patients with osteosarcoma, treatment does not end with surgery and chemotherapy. The risk of recurrence remains a significant challenge, particularly when the disease spreads to the lungs.

OS Therapies is developing OST-HER2, an immunotherapy designed to stimulate an immune response targeting HER2-expressing cancer cells.

Learn more about the science behind OST-HER2: https://bit.ly/4jqxWSg

07/29/2026

The future of antibody-drug conjugates may hinge on a component that often receives the least attention.

In a new interview with BioPharm International, OS Therapies Chairman, CEO and President Paul Romness explains why linker chemistry is emerging as a key area of innovation, with the potential to improve precision drug delivery while reducing exposure to healthy tissue. He also discusses evolving payload strategies and regulatory collaboration in rare disease oncology.

Read the interview:

Paul Romness, chair, chief executive officer, and president of OS Therapies, discusses how advances in linker chemistry, payload design, and evolving regulatory approaches could shape the next generation of antibody–drug conjugates for oncology.

07/29/2026

Immunotherapy is designed to help the body's immune system recognize and respond to cancer.

OS Therapies is focused on developing immunotherapy approaches that harness immune activation as part of cancer treatment research.

Learn more: https://bit.ly/3QX7irr

07/27/2026

HER2 has been studied extensively across oncology, but its role in osteosarcoma is often overlooked.

OST-HER2 was designed specifically to target HER2-expressing cancer cells as part of OS Therapies' approach to osteosarcoma.

Explore the science behind OST-HER2: https://bit.ly/3QX7irr

07/24/2026

Osteosarcoma affects both humans and dogs, creating unique opportunities for comparative oncology research.

Studying naturally occurring disease across species continues to provide important insights that help advance scientific understanding of osteosarcoma.

Learn more: https://bit.ly/3QX7irr

07/22/2026

Osteosarcoma may be rare, but its impact on patients and families is significant.

Continued awareness, research and collaboration remain essential to advancing understanding of the disease and supporting the development of new treatment approaches.

Learn more about OS Therapies and OST-HER2: https://bit.ly/4jqxWSg

07/20/2026

OST-HER2 uses a live-attenuated Listeria monocytogenes platform being developed to deliver HER2-targeted antigens directly into the immune system.

This approach is intended to stimulate immune activity directed toward HER2-expressing tumor cells in osteosarcoma and is being evaluated through ongoing clinical research activities.

Learn more about the technology: https://bit.ly/3QX7irr

07/17/2026

ICYMI: CBER has invited OS Therapies to a Type B Pre-BLA meeting following submission of the non-clinical and Chemistry, Manufacturing and Controls (CMC) BLA modules for OST-HER2 earlier this year.

The invitation was included in the company's announcement that it accepted a new FDA meeting request to review its patent-pending OST-HER2 pharmacodynamic response biomarker data through the FDA's BEST Program.

Read the update: https://bit.ly/4vjJPPM

07/16/2026

Treating osteosarcoma involves more than addressing the initial tumor. One of the greatest challenges is preventing the disease from returning after surgery and chemotherapy.

In a new interview on The Big Biz Show, OS Therapies Chairman, CEO and President Paul Romness explains the scientific rationale behind OST-HER2, how the company's Listeria-based immunotherapy is designed to activate the immune system, recent overall survival data and the company’s regulatory path ahead.

Watch the interview: https://bit.ly/4fFAblO

Paul Romness, Chair, CEO, and President of OS Therapies, talks to o...

07/16/2026

OS Therapies is featured in the latest leadership roundup from pharmaphorum, highlighting the appointment of Dr. Craig Eagle as Chief Medical Advisor.

Since then, Dr. Eagle has also been appointed to the company's Board of Directors, where he continues to support OS Therapies with his oncology and medical affairs background. Thank you for featuring Dr. Eagle's experience across global medical affairs, biomarker development and clinical strategy, as well as his previous leadership roles at Guardant Health, Genentech and Pfizer.

Read more:

Looking back to May, the pharma and biotech sector saw a steady stream of senior leadership changes.